Fluoropyrimidines as Radiation Sensitizers

  • Muhammad Wasif Saif
  • Robert B. Diasio
Part of the Cancer Drug Discovery and Development book series (CDD&D)


Radiation sensitization with concurrent chemotherapy with an aim to improve radioresponse has long been a focus of investigation. As a result of these efforts, the concomitant use of cytostatic drugs and radiation has become the standard approach for many tumors including head and neck, rectal, anal, esophageal, pancreatic, and gastric cancers. The combined chemoradiation offers many potential advantages vs single modality treatment, such as reduction in local failure rates, eradication of micrometastases to enhance distant control, preservation of organ function, and decrease in tumor bulk prior to surgery to make complete resection possible and improve survival.


Rectal Cancer Esophageal Cancer Clin Oncol HT29 Cell Radiat Oncol Biol Phys 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation +5-fluorouracil. Cancer 1981; 48: 1705–1710.PubMedCrossRefGoogle Scholar
  2. 2.
    Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Eng J Med 1985; 312: 1465–1472.CrossRefGoogle Scholar
  3. 3.
    Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Eng J Med 1991; 324: 709–715.CrossRefGoogle Scholar
  4. 4.
    Minsky BD, Cohen AM, Kemeny N, et al. Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J Clin Oncol 1992; 10: 79–84.PubMedGoogle Scholar
  5. 5.
    Ensminger WD, Rosowsky A, Raso V, et al. A clinical pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2’-deoxyuridine and 5-fluorouracil. Cancer Res 1978; 38: 3784–3792.PubMedGoogle Scholar
  6. 6.
    Byfield JE, Barone RM, Frankel SS, et al. Treatment with combined intra-arterial 5-FUdR infusion and whole-liver radiation for colon carcinoma metastatic to the liver. Am J Clin Oncol 1984; 7: 319–325.PubMedCrossRefGoogle Scholar
  7. 7.
    Raju PI, Maruyama Y, DeSimone P, et al. Treatment of liver metastases with a combination of chemotherapy and hyperfractionated external radiation therapy. Am J Clin Oncol 1987; 10: 41–43.PubMedCrossRefGoogle Scholar
  8. 8.
    Lawrence TS, Tepper JE, Blackstock AW. Flouropyrimidine-radiation interaction in cells and tumors. Semin Radiat Oncol 1997; 7: 260–266.PubMedCrossRefGoogle Scholar
  9. 9.
    Monreal M, Davant E. Thrombotic complications of central venous catheters in cancer patients. Acta Haematol 2001; 106 (1–2): 69–72.PubMedCrossRefGoogle Scholar
  10. 10.
    Daher GC, Harris BE, Diasio RB. Metabolism of pyrimidine analogues and their nucleosides. Pharmacol Ther 1990; 48: 189–222.PubMedCrossRefGoogle Scholar
  11. 11.
    Parker WB, Cheg YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 1990; 48: 381–395.PubMedCrossRefGoogle Scholar
  12. 12.
    Miller EM, Kinsella TJ. Radiosensitization by fluorodeoxyuridine: Effects of thymidylate synthase inhibition and cell synchronization. Cancer Res 1992; 52: 1687–1694.PubMedGoogle Scholar
  13. 13.
    Heimburger DK, Shewach DS, Lawrence TS. The effect of fluorodeoxyuridine on sublethal damage repair in human colon cancer cells. Int J Radiat Oncol Biol Phys 1991; 21: 983–987.PubMedCrossRefGoogle Scholar
  14. 14.
    Kufe DW, Scott P, Fram R, et al. Biologic effect of 5-fluoro-2’-deoxyuridine incorporation in L1210 deoxyribonucleic acid. Biochem Pharmcol 1983; 32: 1337–1340.CrossRefGoogle Scholar
  15. 15.
    Danenberg PV, Heidelberger C, Mulkins MA, et al. The incorporation of 5-fluoro-2’-deoxyuridine into DNA of mammalian tumor cells. Biochem Biophys Res Commun 1981; 102: 654–658.PubMedCrossRefGoogle Scholar
  16. 16.
    Goel R, Cleary SM, Horton C, et al. Selective intraperitoneal biochemical modulation of methotrexate by dipyridamole. J Clin Oncol 1989; 7: 262–269.PubMedGoogle Scholar
  17. 17.
    Wilkinson DS, Pitot HC. Inhibition of ribosomal ribonucleic acid maturation in Novikoff hepatoma cells by 5-fluorouracil and 5-fluorouridine. J Biol Chem 1973; 248: 63–68.PubMedGoogle Scholar
  18. 18.
    Greenhalgh DA, Parish JH. Effect of 5-fluorouracil combination therapy on RNA processing in human colonic carcinoma cells. Br J Cancer 1990; 61: 415–419.PubMedCrossRefGoogle Scholar
  19. 19.
    Iwata T, Watanabe T, Kufe DW. Effects of 5-fluorouracil on globin mRNA synthesis in murine erythroleukemia cells. Biochemistry 1986; 25: 2703–2707.PubMedCrossRefGoogle Scholar
  20. 20.
    Dolnick BJ, Pink JJ. Effects of 5-fluorouracil in dihydrofolate reductase and dihydrofolate reductase mRNA from methotrexate-resistant KB cells. J Biol Chem 1985; 260: 3006–3014.PubMedGoogle Scholar
  21. 21.
    Houghton JA, Houghton P, Wooten RS. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorourdine, and 5-fluoro-2’-deoxyuridine. Cancer Res 1979; 39: 2406–2413.PubMedGoogle Scholar
  22. 22.
    Chu E, Zinn S. Boarman D, et al. Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carinoma cell line. Cancer Res 1990; 50: 5834–5840.PubMedGoogle Scholar
  23. 23.
    Wadler S, Wersto R, Weinberg V, et al. Interaction of fluorouracil and interferon in human colon cancer cell lines: Cytotoxic and cytokinetic effects. Cancer Res 1990; 50: 5735–5739.PubMedGoogle Scholar
  24. 24.
    Grem, JL, Mulcahy T, Miller EM, et al. Interaction of deoxyuridine with fluorouracil and dipyridamole in a human colon cancer cell line. Biochem Pharmacol 1989; 38: 51–59.PubMedCrossRefGoogle Scholar
  25. 25.
    Curtin NJ, Harris AL, Aherne GW. Mechanism of cell death following thymidylate synthase inhibition: 2-deoxyuridine-5-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res 1991; 51: 2346–2352.PubMedGoogle Scholar
  26. 26.
    Friedberg EC, Hanawalt PC (eds). DNA Repair, New York; Marcel Dekker, 1988.Google Scholar
  27. 27.
    Ingraham H. Dickey L, Goulian M. DNA fragmentation and cytotoxicity from increased cellular deoxyuridylate. Biochemistry 1986; 25: 3225–3230.PubMedCrossRefGoogle Scholar
  28. 28.
    Hirota Y, Yoshioka A, Tanaka S, et al. Imbalance of deoxyribonucleoside triphosphates, DNA double-strand breaks and cell death caused by 2-chlorodeoxyadenosine in mouse FM3A cells. Cancer Res 1989; 49: 915–919.PubMedGoogle Scholar
  29. 29.
    Yoshioka A. Tanaka S, Hiraoka O, et al. Deoxyribonucleoside triphosphate imbalance. 5-fluorodeoxyuridine-induced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death. J Biol Chem 1987; 262: 8235–8241.PubMedGoogle Scholar
  30. 30.
    Berger SH, Hakala MT. Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil. Mol Pharmacol 1984; 25: 303–309.PubMedGoogle Scholar
  31. 31.
    Sinclair WK. Cyclic X-ray responses in mammalian cells in vitro. Radiat Res 1968; 33: 620–643.PubMedCrossRefGoogle Scholar
  32. 32.
    Terasima T, Tolmach Li. Variation in several responses of Hela cells to x-irradiation during the division cycle. Biophys J 1963; 3: 11–33.PubMedCrossRefGoogle Scholar
  33. 33.
    Byfield JE, Sharp TR, Tang S, et al. Phase I and II trial of cyclical 5-day infused 5-fluorouracil and coincident radiation in advanced cancer of the head of neck. J Clin Oncol 1983; 2: 406–413.Google Scholar
  34. 34.
    Smalley SR, Kimler BF, Evans RG. 5-fluorouracil modulation of radiosensitivity in cultured human carcinoma cells. Int J Radiat Oncol Biol Phys 1991; 20: 207–211.PubMedCrossRefGoogle Scholar
  35. 35.
    Lawrence TS, Davis M, Tang HY, et al. Fluorodeoxyuridine-mediated radiosensitization of human colon cancer cells is not caused by cell cycle redistribution. Proc AACR 1992; 33: 502, (abstr 3002).Google Scholar
  36. 36.
    Bruso CE, Shewach DS, Lawrence TS. Fluorodeoxyuridine-induced radiosensitization and inhibition of DNA double strand break repair in human colon cancer cells. Int J Radiat Oncol Biol Phys 1990; 19: 1411–1417.PubMedCrossRefGoogle Scholar
  37. 37.
    Lawrence TS, Davis MA, Maybaum J, et al. The potential superiority of bromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer. Cancer Res 1992; 52: 3698–3704.PubMedGoogle Scholar
  38. 38.
    Chadwick M, Chang C. Comparative physiologic dispositions of 5-fluoro-2’-deoxyuridine and 5-fluorouracil in mice bearing solid L1210 lymphocytic leukemia. Cancer Treat Rep 1976; 60 (7): 845–855.PubMedGoogle Scholar
  39. 39.
    Myers CE. The pharmacology of the fluoropyrimidines. Pharmacol Rev 1981; 33: 1–15.PubMedGoogle Scholar
  40. 40.
    Byfield JE, Sharp TR, Frankel SS, et al. Phase I and pharmacologic study of 72-hour infused 5-fluorouracil in man. Amer J Clin Oncol 1985; 8: 429–440.CrossRefGoogle Scholar
  41. 41.
    Valerote F, Santelli G. 5-fluorouracil (FUra). Pharmacol Ther 1984; 24: 107–132.CrossRefGoogle Scholar
  42. 42.
    Byfield JE. 5-FU radiation sensitization. Invest New Drugs 1989; 7: 111–116.PubMedCrossRefGoogle Scholar
  43. 43.
    Moertel CG, Schutt AJ, Reitemeier RJ, et al. A comparison of 5-fluorouracil administered by slow infusion and rapid injection. Cancer Res 1972; 32: 2717–2719.PubMedGoogle Scholar
  44. 44.
    Seifert P, Baker LH, Reed ML, et al. A comparison of 5-fluorouracil administered by slow infusion and rapid injection. Cancer Res 1972; 32: 2717–2719.Google Scholar
  45. 45.
    Lokich J. Bothe A, Fine N, et al. Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 1981; 48: 2565–2568.PubMedCrossRefGoogle Scholar
  46. 46.
    Byfield JE. Theoretical basis and clinical applications of 5-fluorouracil used as a radiosensitizer. In: Rosenthal CJ, Rothman M (eds) Clinical Applications of Continuous Infusion Chemotherapy and Concomitant Radiation Therapy, Plenum Publishing Corp. New York, 1986, pp. 113–125.CrossRefGoogle Scholar
  47. 47.
    Byfield JE. The clinical use of 5-fluorouracil and other halopyrimidines as radiosensitizers in man. In: Lokich J (ed) Cancer Chemotherapy by Infusion. Precept Press, Chicago, 1987, pp. 479–501.CrossRefGoogle Scholar
  48. 48.
    Lowe SW, Schmitt EM, Smith SW, et al. p53 is required for radiation-inducted apoptosis in mouse thymocytes. Nature 1993; 362: 847–849.PubMedCrossRefGoogle Scholar
  49. 49.
    Brachman DG, Beckett M, Graves D, et al. p53 mutation does not correlate with radiosensitivity n 24 head and neck cancer cell lines. Cancer Res 1993; 53: 3667–3669.PubMedGoogle Scholar
  50. 50.
    Slichenmyer WJ, Nelson WG, Slebos RJ, et al. Loss of p53-associated GI checkpoint does not decrease cell survival following DNA damage. Cancer Res 1993; 53: 4164–4168.PubMedGoogle Scholar
  51. 51.
    Zellars R, Naida J, Davis MA, et al. The effect of p53 overexpression on radiation sensitivity of human colon cancer cells. Radiat Oncol Investing 1997; 5: 43–49.CrossRefGoogle Scholar
  52. 52.
    Rodrigues NR, Rowan A, Smith MEF, et al. p53 mutations in colorectal cancer. Proc NatlAcad Sci USA 1990; 87: 7555–7559.CrossRefGoogle Scholar
  53. 53.
    Tishler RB, Calderwood SK, Coleman CN, et al. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res 1993; 53: 2212–2216, (suppl).PubMedGoogle Scholar
  54. 54.
    Matsui S, Arrendondo A, Wrzosek C, et al. DNA damage and p53 induction do not cause ZD1694induced cell cycle arrest in human colon carcinoma cells. Cancer Res 1996; 56: 4715–4723.PubMedGoogle Scholar
  55. 55.
    Huber BE, Austin EA, Richards CA, et al. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 1994; 91: 8302–8306.PubMedCrossRefGoogle Scholar
  56. 56.
    Khil MS, Kim JH, Mullen CA, et al. Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene. Clin Cancer Res 1996; 2: 53–57.PubMedGoogle Scholar
  57. 57.
    Ng EY, Rehemtulla A, Laurence TS, et al. Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine. Radiat Res Soc Proc 1977.Google Scholar
  58. 58.
    Hoff PM, Pazdur R, Benner SE, Canetta R. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Anticancer Drugs 1998; 9: 479–490.PubMedGoogle Scholar
  59. 59.
    Budman DR, Meropol NJ, Reigner B, et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 1998; 16: 1795–1802.PubMedGoogle Scholar
  60. 60.
    Takahashi H, Yao K, Sawaki S, Kubota A, Tsukuda M, Miyake H, Horiuchi M, Takeyama I, Kikuchihara M, Kubota T, et al. Investigation of UFT and radiation combination therapy of head and neck cancer mainly in laryngeal cancer. Gan To Kagaku Ryoho 1990; 17: 2037–2042.PubMedGoogle Scholar
  61. 61.
    Fujii M, Nameki H, Kawaura M, et al. A dose finding study of carboplatin (CBDCA) + UFT in head and neck cancer. Proc Am Soc Clin Oncol 1998; 18: 406a (abstr 1564).Google Scholar
  62. 62.
    Rivera F, Lopez-Brea M, Lopez-Vega J, Pascual C, Rubio A, et al. High activity of UFT vinorelbine and cisplatin (UFTVP) as induction chemotherapy for locally advanced squamous cell head and neck carcinoma (SCHNC). Proc Am Soc Clin Oncol 1997; 16: 386a (abstr 1376).Google Scholar
  63. 63.
    Gonzalez-Larriba J, Garcia Carbonero I, Sastre Valera J, Perez Segura P, Diaz-Rubino E. Neoadjuvant therapy with cisplatin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer. Oncology (Huntingt) 1997; 11 (9 Suppl 10): 90–97.Google Scholar
  64. 64.
    Ito H, Takeda Y, Uno T, et al. A Phase I/II trial of UFT and low-dose cisplatin plus concurrent thoracic radiotherapy (TRT) for resected P-N2 non-small cell lung cancer. Proc Am Soc Clin Oncol 1999; 18: 510a (abstr 1966).Google Scholar
  65. 65.
    Ichinose Y, Yano T, Asoh H, et al. UFT plus cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Oncology (Huntingt) 1999; 13 (7 Suppl 3): 98–101.Google Scholar
  66. 66.
    Tsukiyama I, Akine Y, Kajiura Y, et al. Radiation therapy for advanced gastric cancer. IntJRadiat Oncol Biol Phys 1988; 15: 123–127.CrossRefGoogle Scholar
  67. 67.
    Robert F, Raben D, Spencer S. UFT/oral calcium folinate plus radiation in pancreatic cancer. Oncology (Huntingt) 1999; 13 (7 Suppl 3): 127–128.Google Scholar
  68. 68.
    Hoff PM, Janjan N, Saad Ed, et al. Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer. J Clin Oncol 2000; 18: 3529–3534.PubMedGoogle Scholar
  69. 69.
    de la Torre A, Ramos S, Valcarcel FJ, et al. Phase II study of radiochemotherapy with UFT and low-dose oral leucovorin in patients with unresectable rectal cancer. Int J Radiat Oncol Biol Phys 1999; 45: 629–634.PubMedCrossRefGoogle Scholar
  70. 70.
    Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine in human xenografts. Clin Cancer Res 1999; 5 (10): 2948–2953.PubMedGoogle Scholar
  71. 71.
    Dunst J, Reese T, Frings S. Phase I Study of Capecitabine Combined with Simultaneous Radiotherapy Rectal Cancer. ASCO 2001, 149a.Google Scholar
  72. 72.
    Yoon W-H, Choi J-H, Kim J-R, et al. Enhanced Tumoricidal Effect of Preoperative Chemoradiation Using Capecitabine for Locally Advanced Rectal Cancer. ASCO 2001, 104b.Google Scholar
  73. 73.
    Ben-Josef E, Vaishampayan UN, Vaitkevicius VK, et al. A Single Institution Experience with Concurrent Capecitabine and Radiation Therapy in Gastrointestinal Malignancies. ASCO 2001, 1436.Google Scholar
  74. 74.
    Byfield JE, Barone R, Mendelsohn J, et al. Infusional 5-fluorouracil and X-ray therapy for non-resectable esophageal cancer. Cancer 1980; 45: 703–708.PubMedCrossRefGoogle Scholar
  75. 75.
    Coia LR, Engstrom PF, Paul AR, et al. Long-term results of infusional 5-FU, mitomycin-C, and radiation as primary management of esophageal carcinoma. Int J Radiat Oncol Biol Phys 1991; 20: 29–36.PubMedCrossRefGoogle Scholar
  76. 76.
    Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326: 1593–1598.PubMedCrossRefGoogle Scholar
  77. 77.
    Al-Sarraf M, Pajak T, Herskovic A, et al. Progress report of combined chemo-radiotherapy (CT-RT) vs radiotherapy (RT) alone in patients with esophageal cancer. An intergroup study. Proc Annu Meet Am Soc Clin Oncol 1993; 12: 197.Google Scholar
  78. 78.
    Kalser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120: 899–903.PubMedCrossRefGoogle Scholar
  79. 79.
    Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988; 80: 751–755.CrossRefGoogle Scholar
  80. 80.
    O’Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 331: 502–507.PubMedCrossRefGoogle Scholar
  81. 81.
    Nigro ND, Vaitkevicius VK, Considine B. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 1974; 17: 354–356.PubMedCrossRefGoogle Scholar
  82. 82.
    Flam MS, John JM, Pajak T, et al. Radiation (RT) and 5-fluorouracil (5-FU) vs radiation, 5-FU, mitomycin-C (MMC) in the treatment of anal carcinoma: results of a phase III randomized RTOG/ ECOG intergroup trial. Proc Annu Meet Am Soc Clin Oncol 1995; 14:191. Abstract A443.Google Scholar
  83. 83.
    Mahjoubi M, Sadek H, Francois E, et al. Epidermoid anal canal carcinoma (EACC): activity of cisplatin and continuous 5-fluorouracil in metastatic and/or local recurrent disease. Proc Annu Meet Am Soc Clin Oncol 1990; 9: 114.Google Scholar
  84. 84.
    Martenson JA, Lipitz S, Wagner H, et al. Phase II trial of radiation therapy, 5-fluorouracil and cisplatin in patients with anal cancer. Inr J Radiar Oncol Biol Phys 1995; 32 (suppl 1): 158.CrossRefGoogle Scholar
  85. 85.
    Robertson JM, Lawrence TS, Walker S. The treatment of colorectal liver metastases with conformal radiation therapy and regional chemotherapy. Int J Rad Oncol Biol Phys 1995; 32: 445–450.CrossRefGoogle Scholar
  86. 86.
    Russel KJ, Bioleau MA, Higano C. Combined 5-FU and irradiation for transitional cell carcinoma of the urinary bladder. Ina J Rad Oncol Biol Phys 1990; 19: 693–699.CrossRefGoogle Scholar
  87. 87.
    Rotman M, Macchia R, Silverstein M. Treatment of advanced bladder carcinoma with irradiation and concomitant 5-FU infusion. Cancer 1987; 59: 710–714.PubMedCrossRefGoogle Scholar
  88. 88.
    Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer: The Department of Veterans Affairs Laryngeal Cancer Study Group. N Eng J Med 1991; 324: 1685–1690.Google Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Muhammad Wasif Saif
  • Robert B. Diasio

There are no affiliations available

Personalised recommendations